Corient Private Wealth LLC Grows Stock Holdings in Thermo Fisher Scientific Inc. $TMO

Corient Private Wealth LLC grew its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 4.5% in the fourth quarter, Holdings Channel.com reports. The firm owned 765,477 shares of the medical research company’s stock after acquiring an additional 33,280 shares during the quarter. Corient Private Wealth LLC’s holdings in Thermo Fisher Scientific were worth $443,556,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in TMO. Strive Financial Group LLC acquired a new position in Thermo Fisher Scientific during the fourth quarter worth $2,209,000. Blue Sparrow LLC DE acquired a new stake in shares of Thermo Fisher Scientific in the 4th quarter worth $16,167,000. Mercer Global Advisors Inc. ADV boosted its position in shares of Thermo Fisher Scientific by 13.7% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 38,903 shares of the medical research company’s stock valued at $22,543,000 after acquiring an additional 4,697 shares during the last quarter. Summit Global Investments purchased a new stake in shares of Thermo Fisher Scientific in the fourth quarter valued at about $1,076,000. Finally, Raymond James Financial Inc. increased its position in Thermo Fisher Scientific by 1.4% during the fourth quarter. Raymond James Financial Inc. now owns 760,643 shares of the medical research company’s stock worth $440,758,000 after purchasing an additional 10,814 shares during the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have weighed in on TMO. Morgan Stanley reiterated an “overweight” rating and issued a $620.00 target price on shares of Thermo Fisher Scientific in a report on Monday, April 27th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Thermo Fisher Scientific in a research report on Wednesday, April 8th. Stifel Nicolaus decreased their price objective on Thermo Fisher Scientific from $700.00 to $600.00 and set a “buy” rating on the stock in a report on Friday, April 24th. Wolfe Research started coverage on Thermo Fisher Scientific in a research note on Tuesday, June 2nd. They set an “outperform” rating and a $535.00 target price for the company. Finally, Jefferies Financial Group upgraded Thermo Fisher Scientific to a “strong-buy” rating in a research report on Friday, April 24th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $608.95.

Insider Activity

In related news, COO Gianluca Pettiti sold 400 shares of the stock in a transaction dated Monday, April 27th. The stock was sold at an average price of $462.66, for a total transaction of $185,064.00. Following the transaction, the chief operating officer owned 25,051 shares of the company’s stock, valued at approximately $11,590,095.66. This represents a 1.57% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Price Performance

Thermo Fisher Scientific stock opened at $465.98 on Friday. The company’s 50 day simple moving average is $477.34 and its 200-day simple moving average is $523.72. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.15 and a current ratio of 1.53. Thermo Fisher Scientific Inc. has a 1 year low of $390.50 and a 1 year high of $643.99. The company has a market capitalization of $173.17 billion, a price-to-earnings ratio of 25.62, a price-to-earnings-growth ratio of 2.04 and a beta of 0.88.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Thursday, April 23rd. The medical research company reported $5.44 earnings per share for the quarter, topping analysts’ consensus estimates of $5.25 by $0.19. The firm had revenue of $11.01 billion during the quarter, compared to analysts’ expectations of $10.86 billion. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The firm’s quarterly revenue was up 6.2% on a year-over-year basis. During the same quarter last year, the company posted $5.15 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. As a group, equities research analysts expect that Thermo Fisher Scientific Inc. will post 24.85 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 15th. Stockholders of record on Monday, June 15th will be paid a $0.47 dividend. The ex-dividend date of this dividend is Monday, June 15th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.4%. Thermo Fisher Scientific’s payout ratio is presently 10.34%.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.